MediciNova, Inc. (NASDAQ:MNOV) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Analysts have set a 12 month consensus target price of $20.67 for the company and are expecting that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also assigned MediciNova an industry rank of 90 out of 256 based on the ratings given to its competitors.
Separately, BidaskClub lowered shares of MediciNova from a “sell” rating to a “strong sell” rating in a report on Friday.
NASDAQ:MNOV traded up $0.64 during mid-day trading on Wednesday, reaching $9.01. 6,863 shares of the company were exchanged, compared to its average volume of 108,841. MediciNova has a 12 month low of $6.68 and a 12 month high of $13.37. The company has a fifty day moving average of $9.37 and a 200 day moving average of $9.62. The stock has a market cap of $353.36 million, a PE ratio of -24.94 and a beta of 1.19.
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
Featured Article: Understanding Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.